Go offline with the Player FM app!
Episode 10. Castleman Disease
Manage episode 348464574 series 3369804
Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease
International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment
Somatic alterations in Castleman Disease:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/
https://www.nature.com/articles/s41375-018-0323-6
Rituximab + Liposomal Doxorubicin in HHV8-positive MCD:
https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIV
RCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/
Long-term data on Siltuximab in MCD: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30257-1/fulltext
50 episodes
Manage episode 348464574 series 3369804
Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease
International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment
Somatic alterations in Castleman Disease:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/
https://www.nature.com/articles/s41375-018-0323-6
Rituximab + Liposomal Doxorubicin in HHV8-positive MCD:
https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIV
RCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/
Long-term data on Siltuximab in MCD: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30257-1/fulltext
50 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.